A detailed history of Mathes Company, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Mathes Company, Inc. holds 582 shares of LLY stock, worth $594,629. This represents 0.16% of its overall portfolio holdings.

Number of Shares
582
Previous 435 33.79%
Holding current value
$594,629
Previous $339,000 30.97%
% of portfolio
0.16%
Previous 0.13%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$625.65 - $812.69 $91,970 - $119,465
147 Added 33.79%
582 $444,000
Q2 2025

Aug 05, 2025

SELL
$713.71 - $898.95 $363,992 - $458,464
-510 Reduced 53.97%
435 $339,000
Q1 2025

May 01, 2025

BUY
$725.72 - $929.72 $279,402 - $357,942
385 Added 68.75%
945 $780,000
Q4 2024

Jan 31, 2025

BUY
$727.2 - $932.06 $407,232 - $521,953
560 New
560 $432,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $971B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Mathes Company, Inc. Portfolio

Follow Mathes Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mathes Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mathes Company, Inc. with notifications on news.